For information on use of the individual components when dispensed as individual medications outside this combined use for treating Helicobacter pylori, please see the package inserts for each individual product.
Omeclamox®-Pak (omeprazole, clarithromycin, amoxicillin) is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
IMPORTANT SAFETY INFORMATION
- No adverse events unique to triple therapy were observed. Adverse reactions were limited to those previously reported with omeprazole, clarithromycin or amoxicillin alone.
- The most frequent adverse events with Omeclamox®-Pak were diarrhea, headache and taste perversion.
- Omeclamox®-Pak is contraindicated in patients with known hypersensitivity to omeprazole, and macrolide antibiotic, any penicillin or any component of the formulations.
- Amoxicillin is contraindicated in patients who are allergic to penicillin.
- Clarithromycin is contraindicated in patients taking ergotamine or dihydroergotamine and pimozide. Clarithromycin may elevate digoxin serum concentrations. Serum digoxin levels should be carefully monitored while digoxin and clarithromycin are taken concomitantly.
- Clarithromycin should not be used in pregnant women except in circumstances where no alternative therapy is appropriate.
- If clarithromycin resistance is demonstrated, a non-clarithromycin therapy is recommended. If possible, susceptibility testing should be done in patients who fail therapy.
- Concomitant use of clarithromycin and colchicine has resulted in deaths, especially in the elderly with renal insufficiency. Monitor patients for clinical symptoms of colchicine toxicity.
- Exacerbation of symptoms and new onset of symptoms in patients with myasthenia gravis have been reported with clarithromycin. Monitor patients for symptoms.
- Clostridium difficile-associated diarrhea has been reported with use of clarithromycin and amoxicillin; evaluate if diarrhea occurs.
- Symptomatic response to therapy with omeprazole does not preclude the presence of gastric malignancy.
- Acute interstitial nephritis has been observed in patients taking PPIs.
- Cutaneous and Systematic Lupus Erythematosus, most cutaneous, have been reported in patients taking PPIs, including omeprazole. If this occurs, discontinue Omeclamox®-Pak and refer to specialist for evaluation.
- Due to the clarithromycin and amoxicillin components of Omeclamox®-Pak, the possibility of superinfections exist. Discontinue Omeclamox®-Pak and institute appropriate therapy.
- Administration of ampicillin class antibiotics in patients with mononucleosis is not recommended.
- Prescribing clarithromycin or amoxicillin in the absence of a bacterial infection or prophylactic indication increases risk of the development of drug-resistant bacteria and is unlikely to provide patient benefit.
†Omeclamox®-Pak is a registered trademark of GastroEntero-Logic, LLC.
װPrevPac® is a registered trademark of Takeda Pharmaceuticals U. S. A. Inc.
¶Pylera® is a registered trademark of Aptalis Pharma Canada Inc., an affiliate of Aptalis Pharma US, Inc.
1. Omeclamox®-Pak complete prescribing information. 03/2017
2. PrevPac® complete prescribing information. Available at: http://general.takedapharm.com/content/file/pi.pdf?filetypecode=PREVPACPI. Retrieved March 1, 2017.
3. Pylera® complete prescribing information. Available at: https://www.allergan.com/assets/pdf/pylera_pi. Retrieved March 1, 2017.